Prescribing information

 

Please note that the black triangle (▼) and associated additional monitoring activities required for Kisqali®, only applies to its marketing authorisation in Great Britain. It is NOT applicable to the marketing authorisation of Kisqali® in Northern Ireland.

 

KISQALI Your Choice+ is a flexible patient support programme, now enhanced to include dispense and delivery, and administration of fulvestrant.

KISQALI Your Choice+ aims to optimise treatment outcomes for patients with HR+/HER2− locally advanced or metastatic breast cancer (mBC) prescribed KISQALI and aromatase inhibitor (AI) or KISQALI and fulvestrant. The KISQALI Your Choice+ programme offers:

  • Nurse support to monitor your patients in the COMFORT of their own home
  • CONFIDENCE in a streamlined end-to-end service tailored to your and your patients’ needs
  • DISPENSE AND DELIVERY of AI or fulvestrant, plus administration of fulvestrant

What are the benefits of KISQALI Your Choice+?

down pointing arrow icon

Assists with treatment monitoring at a location convenient to the patient, e.g. at home or at work

down pointing arrow icon

Reinforces education provided by the patient’s healthcare team and manages the patient’s expectations around treatment and adverse events with KISQALI

down pointing arrow icon

Reduces logistical challenges for patients, minimising the frequency and length of hospital visits

down pointing arrow icon

Complements existing support from the patient’s NHS team, ensuring the best possible treatment experience with KISQALI

down pointing arrow icon

Additional dedicated nurse touchpoints help to optimise treatment outcomes by ensuring patients are given the best chance of remaining adherent to treatment

 

A comprehensive support programme for you and your patients

Fully funded by Novartis Ltd, KISQALI Your Choice+ is delivered in partnership with Pharmaxo Pharmacy Services Ltd. Pharmaxo is an experienced national provider of high-quality specialist care to patients in their own homes. Their services include medication dispensing and delivery to patients, and nursing services in the form of in-home patient support, product training, and education.

KISQALI Your Choice+ can be tailored to meet both your needs and those of your patients

Patients enrolled onto KISQALI Your Choice+ can choose to receive dispense and delivery of their treatment and will be assigned a dedicated nurse. This nurse will provide patients with monitoring support to complement and enhance existing services from their NHS clinical team.

Existing features of KISQALI Your Choice+ service KISQALI and AI KISQALI and fulvestrant
Welcome call from nurse
ECG
Bloods – FBC/LFT/electrolytes
Education and materials

Latest features now added to the Your Choice+ service:

  KISQALI and AI KISQALI and fulvestrant
Regular nurse visits for duration of treatment* As required
Fulvestrant administration N/A
Home delivery† service for duration of treatment

 

*Patients treated with KISQALI and AI will receive nurse support for the first 6 months of treatment and as clinically indicated thereafter (this will be agreed on a case by case basis).
Home delivery is only available if Letrozole (marketed by Novartis) or anastrozole (marketed by Sandoz) are selected by the treating physician in the case of KISQALI
+ AI, or if the generic fulvestrant (marketed by Sandoz) is selected in the case of KISQALI + fulvestrant.

Patients treated with KISQALI and fulvestrant will receive nurse support for the duration of their treatment.

  • Face-to-face monitoring support is provided at a location which is convenient for your patient
    • Bloods are taken and delivered to hospital (or other selected NHS location) for testing
    • ECGs are performed and a report prepared for the patient’s NHS clinical team
  • For first-line treatment with KISQALI and AI:
    • Patients who select nurse only support, the AI selected is at the discretion of the treating clinician
    • Patients who select both nurse support and dispense and delivery, the AI must be letrozole (Novartis) or anastrozole (Sandoz).**
  • For second-line treatment with KISQALI and fulvestrant:
    • The fulvestrant included with this programme is manufactured by Sandoz
  • All patients who select dispense and delivery will benefit from this for the duration of their treatment
  • Treatment is delivered to the patient’s home or named location every three months, unless otherwise requested by the clinician and approved by Novartis

 

Who to contact if you are interested in KISQALI Your Choice+

 

For more information, please contact your local Novartis representative who will forward your interest to the relevant Novartis associate to arrange a clinical pathway meeting with Pharmaxo.

This meeting will allow you to design and agree on the service that is best suited to you and your patients, including the most appropriate patient journey and feedback mechanisms.

 

**There is no obligation on the treating clinician to use this option of the service, and the choice of AI used must always be made at the discretion of the treating clinician.

 

Download the KISQALI Your Choice+ guides for HCPs and patients for more information

KISQALI Your Choice+ HCP booklet

Download this guide to find out more about how the KISQALI Your Choice+ programme works and the benefits it could bring to you and your patients

Download

KISQALI Your Choice+: KISQALI + AI patient booklet

For your patients who have already been prescribed KISQALI and an AI, this booklet has been developed to help provide them with more information on the KISQALI Your Choice+ programme and how their treatments may be delivered and monitored.

Download

KISQALI Your Choice+: KISQALI + fulvestrant patient booklet

For your patients who have already been prescribed KISQALI and fulvestrant, this booklet has been developed to help provide them with more information on the KISQALI Your Choice+ programme and how their KISQALI + fulvestrant treatments may be delivered, administered and monitored.

Download

KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist1 

AI, aromatase inhibitor; ECG, electrocardiogram; FBC, full blood count; HCP, healthcare professional; HR, hormone receptor; HR+/HER2−, hormone receptor positive/human epidermal growth factor receptor 2 negative; LFT, liver function test; LHRH, luteinising hormone-releasing hormone; mBC, metastatic breast cancer; NHS, National Health Service.

  1. KISQALI (ribociclib). Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | April 2022 | 196868
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]